
MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model
Keywords: Pancreatic cancer; PDOX; Trametinib; Gemcitabine; Combination; Cancer resistance; Indvidualized therapy; Precision medicine;